Mereo BioPharma Statistics Share Statistics Mereo BioPharma has 159M
shares outstanding. The number of shares has increased by 359.33%
in one year.
Shares Outstanding 159M Shares Change (YoY) 359.33% Shares Change (QoQ) 2.48% Owned by Institutions (%) 13.31% Shares Floating 132.68M Failed to Deliver (FTD) Shares 10 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 9.84M, so 6.19% of the outstanding
shares have been sold short.
Short Interest 9.84M Short % of Shares Out 6.19% Short % of Float 8.71% Short Ratio (days to cover) 1.5
Valuation Ratios The PE ratio is -11.97 and the forward
PE ratio is -38.25.
Mereo BioPharma's PEG ratio is
0.12.
PE Ratio -11.97 Forward PE -38.25 PS Ratio 0 Forward PS 7.4 PB Ratio 8.49 P/FCF Ratio -15.44 PEG Ratio 0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Mereo BioPharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.4,
with a Debt / Equity ratio of 0.11.
Current Ratio 5.4 Quick Ratio 5.4 Debt / Equity 0.11 Debt / EBITDA -0.14 Debt / FCF -0.19 Interest Coverage -34.56
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.2M Employee Count 36 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 18.2K Effective Tax Rate -0.04%
Stock Price Statistics The stock price has increased by -59.41% in the
last 52 weeks. The beta is 0.42, so Mereo BioPharma's
price volatility has been higher than the market average.
Beta 0.42 52-Week Price Change -59.41% 50-Day Moving Average 2.26 200-Day Moving Average 2.82 Relative Strength Index (RSI) 28.89 Average Volume (20 Days) 2,265,190
Income Statement
Revenue n/a Gross Profit n/a Operating Income -47.36M Net Income -43.25M EBITDA -47.36M EBIT -44.62M Earnings Per Share (EPS) -0.29
Full Income Statement Balance Sheet The company has 69.8M in cash and 6.43M in
debt, giving a net cash position of 63.37M.
Cash & Cash Equivalents 69.8M Total Debt 6.43M Net Cash 63.37M Retained Earnings -462.88M Total Assets 68.32M Working Capital 59.4M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -32.83M
and capital expenditures -699K, giving a free cash flow of -33.53M.
Operating Cash Flow -32.83M Capital Expenditures -699K Free Cash Flow -33.53M FCF Per Share -0.23
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
